Hematologic Diseases: Clinical Trials

3,488 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3488 completed. 3488 Phase 2, 754 Phase 1, 147 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23488Completed 3488
Phase 1754Completed 754
Phase 3147Completed 147

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 3,488 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients
Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major)
Phase 2CompletedAin Shams University1002026-01-012026-10-07
Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis
Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis
Phase 2CompletedUniversitas Sebelas Maret502025-08-142026-10-23
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
PN20, Placebo - Thrombocytopenia Associated With Chronic Liver Disease
Phase 1 / Phase 2CompletedChongqing Peg-Bio Biopharm Co., Ltd.542025-06-062026-10-22
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
XH-S003 Capsule - PNH - Paroxysmal Nocturnal Hemoglobinuria
Phase 2CompletedShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.262025-05-212026-11-18
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
HBI-002 - Anemia, Sickle Cell
Phase 2CompletedHillhurst Biopharmaceuticals, Inc.132025-02-152026-08-06
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
zinc sulfate, Placebo - Sickle Cell Disease
Phase 2 / Phase 3CompletedIndiana University1002025-02-102026-01-30
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
Phase 1 / Phase 2CompletedNational Research Center for Hematology, Russia582024-11-262026-02-09
A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)
HSK39297 - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2CompletedHaisco Pharmaceutical Group Co., Ltd.472024-07-172025-06-29
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
Foscenvivint - Liver Cirrhosis
Phase 2CompletedKiminori Kimura, MD52024-05-082026-05-01
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Lusutrombopag Oral Tablet - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China172024-04-172025-12-19
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2CompletedChongqing Precision Biotech Co., Ltd52024-03-282026-08-05
Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome
Phase 2CompletedLiu Tian82024-03-242026-05-13
Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
STSP-0601 for Injection - Hemophilia
Phase 2CompletedStaidson (Beijing) Biopharmaceuticals Co., Ltd252024-03-182025-01-22
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Etavopivat - Sickle Cell Disease
Phase 2CompletedNovo Nordisk A/S122024-03-092026-04-08
Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia
Ferric Carboxymaltose (FCM) - Anemia, Anemia, Postpartum
Phase 2 / Phase 3CompletedESI-PGIMSR, Basaidarapur2002024-03-012026-06-15
Study of AZD9829 in CD123+ Hematological Malignancies
AZD9829 - Hematological Malignancies
Phase 1 / Phase 2CompletedAstraZeneca562024-01-312026-07-01
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Epeleuton - Sickle Cell Disease
Phase 2CompletedAfimmune352024-01-102026-05-04
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
HT-6184 - Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
Phase 2CompletedHalia Therapeutics, Inc.372023-12-092026-11-10
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
AD17002, Placebo - Eosinophilic Asthma
Phase 1 / Phase 2CompletedAdvagene Biopharma Co. Ltd.402023-11-272025-09-10
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
HRS-5965 tablets - Paroxysmal Nocturnal Hemoglobinuria
Phase 2CompletedChengdu Suncadia Medicine Co., Ltd.262023-11-152024-10-15

Showing 20 of 3488. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (747)  ·  Leukemia, Myeloid, Acute (698)  ·  Leukemia (651)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (510)  ·  Myelodysplastic Syndromes (494)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (452)  ·  Lymphoma (311)  ·  Lymphoma, Non-Hodgkin (295)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228)  ·  Lymphoma, Follicular (223)  ·  Recurrence (199)  ·  Hodgkin Disease (198)  ·  Lymphoma, Mantle-Cell (196)  ·  Lymphoma, B-Cell, Marginal Zone (193)  ·  Neoplasms, Plasma Cell (193)

Broader conditions

Hemic and Lymphatic Diseases (3488)  ·  Neoplasms (2462)  ·  Neoplasms by Histologic Type (2378)  ·  Immune System Diseases (1849)  ·  Immunoproliferative Disorders (1648)  ·  Lymphoproliferative Disorders (1622)  ·  Pathological Conditions, Signs and Symptoms (1235)  ·  Pathologic Processes (1198)  ·  Lymphatic Diseases (1083)  ·  Leukemia (1057)  ·  Hemorrhagic Disorders (1049)  ·  Disease Attributes (1047)  ·  Bone Marrow Diseases (999)  ·  Leukemia, Myeloid (927)

Interventions

Cyclophosphamide (406)  ·  Dexamethasone (299)  ·  Cytarabine (242)  ·  fludarabine phosphate (222)  ·  Lenalidomide (202)  ·  Rituximab (190)  ·  Filgrastim (188)  ·  Melphalan (170)  ·  Bortezomib (162)  ·  Busulfan (157)  ·  Peripheral Blood Stem Cell Transplantation (156)  ·  fludarabine (156)  ·  Methotrexate (147)  ·  Cyclosporine (127)  ·  Mycophenolic Acid (127)

Sponsors

M.D. Anderson Cancer Center (215)  ·  National Cancer Institute (NCI) (140)  ·  Fred Hutchinson Cancer Center (117)  ·  Novartis Pharmaceuticals (83)  ·  Memorial Sloan Kettering Cancer Center (79)  ·  Mayo Clinic (65)  ·  National Heart, Lung, and Blood Institute (NHLBI) (60)  ·  Amgen (48)  ·  Celgene (43)  ·  Dana-Farber Cancer Institute (43)  ·  H. Lee Moffitt Cancer Center and Research Institute (37)  ·  GlaxoSmithKline (33)  ·  Bristol-Myers Squibb (32)  ·  Masonic Cancer Center, University of Minnesota (31)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (31)

Countries

United States (2310)  ·  Germany (329)  ·  France (315)  ·  Italy (304)  ·  Canada (299)  ·  United Kingdom (265)  ·  Spain (199)  ·  Australia (141)  ·  China (125)  ·  Japan (111)  ·  Netherlands (110)  ·  Poland (110)  ·  Belgium (103)  ·  South Korea (101)  ·  Austria (94)

Top investigators

Brenda Sandmaier (13)  ·  Jorge Cortes, MD (12)  ·  Guillermo Garcia-Manero, MD (10)

Results publications

PMID 36005278, PMID 32499241, PMID 33783815, PMID 23524640, PMID 34724566, PMID 23065508, PMID 30957581, PMID 34515338, PMID 35622074, PMID 23738544, PMID 27209293, PMID 29358183, PMID 29674506, PMID 30062662, PMID 34175041, PMID 35549810, PMID 36184192, PMID 36240296, PMID 19216617, PMID 23620574, PMID 25361995, PMID 27658437, PMID 28835440, PMID 29958797, PMID 30885996, PMID 31171508, PMID 31221778, PMID 33242441, PMID 34922648, PMID 35235189, PMID 36791280, PMID 37934000, PMID 37975597, PMID 40156952, PMID 17715389, PMID 18596230, PMID 18997171, PMID 19005182, PMID 19667400, PMID 19846889, PMID 20661232, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22067384, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24383844

NIH funding

P30CA015704 (49), P30CA015083 (44), U10CA031946 (34), 2017 (29), 2016 (28), 2015 (27), 2008 (26), 2014 (25), 2009 (24), U10CA032102 (24), P30CA006973 (23), 2005 (22), 2018 (21), P30CA016672 (16), P01CA018029 (15)